GigaMune wins eighth SBIR grant

GigaMune won its eighth SBIR grant, entitled “In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle” from the National Institute of Allergy and Infectious Diseases (NIAID). The project seeks to expand the capabilities of GigaMune’s technology into delivery of curative transgenes to hematopoietic stem cells (HSCs). GigaMune’s Founder and CEO Dr. David Johnson is principal investigator (PI) on the project. This is Dr. Johnson’s twentieth SBIR grant as PI.